Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis

被引:16
作者
Dimitroulas, Theodoros [1 ]
Daoussis, Dimitrios [2 ]
Garyfallos, Alexandros [3 ]
Sfikakis, Petros P. [4 ]
Kitas, George D. [1 ,5 ]
机构
[1] Univ Birmingham, Dept Rheumatol, Russells Hall Hosp, Dudley Grp NHS Fdn Trust,Teaching Trust, Dudley, England
[2] Patras Univ Hosp, Div Rheumatol, Dept Internal Med, Patras, Greece
[3] Hippokrateion Hosp, Dept Internal Med 4, Thessaloniki, Greece
[4] Univ Athens, Sch Med, Dept Propedeut Internal Med 1, GR-11527 Athens, Greece
[5] Univ Manchester, Arthritis Res UK Epidemiol Unit, Manchester, Lancs, England
基金
英国医学研究理事会;
关键词
Systemic Sclerosis; fibrosis; biologic therapies; Rituximab; Tocilizumab; INTERSTITIAL LUNG-DISEASE; NECROSIS-FACTOR-ALPHA; PULMONARY ARTERIAL-HYPERTENSION; PLACEBO-CONTROLLED TRIAL; LOW-DOSE IMATINIB; SKIN FIBROSIS; OPEN-LABEL; MYCOPHENOLATE-MOFETIL; RAYNAUDS-PHENOMENON; MOUSE MODEL;
D O I
10.2174/0929867322666150209161224
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent advances have shed light on the complex pathogenic processes that underlie the development and progression of Systemic Sclerosis (SSc) but management of the disease remains problematic and curative treatment is not available. Better understanding of the underlying pathology has enabled novel therapeutic approaches to be investigated, as therapies in rheumatology are becoming increasingly disease/organ-specific, targeting unique biological networks and signalling pathways. The pathophysiologic and clinical pleiomorphism of SSc however, represents a major barrier to conducting large well-controlled studies for the evaluation of non-selective immunosuppressive and novel highly selective agents. Therapeutic biologic strategies targeting inflammatory or profibrotic cytokines and lymphocyte activation proved to be efficacious in other systemic rheumatic diseases but have demonstrated contradictory results in SSc. Blocking of tumour necrosis factor alpha and interleukin-6 may improve SSc-associated arthritis, while depletion of B-cells may have benefits for skin and lung fibrosis, but randomized studies are needed. In this review we critically appraise available data for the treatment of SSc focusing on immunologic and antifibrotic strategies. Attenuation of the fibrotic process remains an unmet goal but the potential to prevent damage by promoting tissue repair has been shown in preclinical studies. Translation of these findings into clinical practice will hopefully establish new therapeutic options and improve prognosis of these patients, for which our therapeutic armamentarium remains poor.
引用
收藏
页码:1943 / 1955
页数:13
相关论文
共 144 条
[91]   Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease? [J].
Papadakis, Vassilios ;
Karakasis, Dimitri ;
Sfikakis, Petros P. ;
Baltadakis, Ioannis ;
Apostolidis, John ;
Evangelou, Kostas ;
Gorgoulis, Vassilis G. ;
Harhalakis, Nikolaos .
LEUKEMIA & LYMPHOMA, 2009, 50 (03) :471-474
[92]   Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases [J].
Perez-Alvarez, Roberto ;
Perez-de-Lis, Marta ;
Diaz-Lagares, Candid ;
Pego-Reigosa, Jose M. ;
Retamozo, Soledad ;
Bove, Albert ;
Brito-Zeron, Pilar ;
Bosch, Xavier ;
Ramos-Casals, Manuel .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (02) :256-264
[93]   Biologic Therapy for Systemic Sclerosis: A Systematic Review [J].
Phumethum, Veerapong ;
Jamal, Shahin ;
Johnson, Sindhu R. .
JOURNAL OF RHEUMATOLOGY, 2011, 38 (02) :289-296
[94]   Effect of mycophenolate sodium in scleroderma-related interstitial lung disease [J].
Pilar Simeon-Aznar, Carmen ;
Fonollosa-Pla, Vicent ;
Tolosa-Vilella, Carles ;
Selva-O'Callaghan, Albert ;
Solans-Laque, Roser ;
Vilardell-Tarres, Miquel .
CLINICAL RHEUMATOLOGY, 2011, 30 (11) :1393-1398
[95]   Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis [J].
Poormoghim, Hadi ;
Lakeh, Maziar Moradi ;
Mohammadipour, Mastoureh ;
Sodagari, Faezeh ;
Toofaninjed, Neda .
RHEUMATOLOGY INTERNATIONAL, 2012, 32 (08) :2431-2444
[96]   Imatinib in Active Diffuse Cutaneous Systemic Sclerosis: Results of a Six-Month, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Pilot Study at a Single Center [J].
Pope, Janet ;
McBain, Donna ;
Petrlich, Lisa ;
Watson, Sharon ;
Vanderhoek, Louise ;
de Leon, Faye ;
Seney, Shannon ;
Summers, Kelly .
ARTHRITIS AND RHEUMATISM, 2011, 63 (11) :3547-3551
[97]   CONNECTIVE TISSUE DISEASES New evidence-based guidelines for treating SSc [J].
Pope, Janet E. .
NATURE REVIEWS RHEUMATOLOGY, 2009, 5 (06) :300-302
[98]   Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial [J].
Prey, S. ;
Ezzedine, K. ;
Doussau, A. ;
Grandoulier, A. -S. ;
Barcat, D. ;
Chatelus, E. ;
Diot, E. ;
Durant, C. ;
Hachulla, E. ;
de Korwin-Krokowski, J. -D. ;
Kostrzewa, E. ;
Quemeneur, T. ;
Paul, C. ;
Schaeverbeke, T. ;
Seneschal, J. ;
Solanilla, A. ;
Sparsa, A. ;
Bouchet, S. ;
Lepreux, S. ;
Mahon, F. -X. ;
Chene, G. ;
Taieb, A. .
BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (05) :1138-1144
[99]   Autoimmune-like syndromes during TNF blockade: does infection have a role? [J].
Prinz, Joerg C. .
NATURE REVIEWS RHEUMATOLOGY, 2011, 7 (07) :429-434
[100]   Expression of TGF-β1, -β2 and -β3 in localized and systemic scleroderma [J].
Querfeld, C ;
Eckes, B ;
Huerkamp, C ;
Krieg, T ;
Sollberg, S .
JOURNAL OF DERMATOLOGICAL SCIENCE, 1999, 21 (01) :13-22